scholarly journals The Effect of Hemodialysis Treatment on Ventricular Arrhythmogenesis Parameters in Electrocardiography

2021 ◽  
Vol 1 (37) ◽  
pp. 5-10 ◽  
Author(s):  
Isa Ardahanli ◽  
Okan Akyuz
Keyword(s):  
Hemodialysis Treatment ◽  
Ventricular Arrhythmogenesis

Should the Lopot-Plot Be Used in Daily Practice to Optimise Hemodialysis Treatment?

2012 ◽  
Vol 8 (4) ◽  
pp. 417-423
Author(s):  
Przemysław Korohoda ◽  
Przemysław Sypka ◽  
Jacek A. Pietrzyk
Keyword(s):  
Steady State ◽  
Planning Process ◽  
Computational Study ◽  
Daily Practice ◽  
Urea Concentration ◽  
Hemodialysis Treatment

ABSTRACT The paper presents an application of the Lopot-plot, which compares the timeaveraged concentration (TAC) and the time-averaged deviation (TAD) of the weekly dialysis cycle, to comprise the results of intensive computational study. The presented case is based on 420 one-week-cycle simulations to verify the consequences implied by the change of the treatments schedule from nonuniformly to uniformly distributed over the week. The concept of steady state is explained and utilized to obtain periodical runs of the urea concentration. The presented graphs encouragingly indicate the potential of such plots in presenting results of multivariable intensive computations that should be advisably performed during the planning process of hemodialysis treatment.

scholarly journals Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients

Toxins ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 289
Author(s):  
Adamasco Cupisti ◽  
Piergiorgio Bolasco ◽  
Claudia D’Alessandro ◽  
Domenico Giannese ◽  
Alice Sabatino ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Residual Renal Function ◽  
The Body ◽  
Uremic Toxins ◽  
End Stage Kidney Disease ◽  
Waste Products ◽  
Hemodialysis Treatment ◽  
Life Saving ◽  
Kidney Replacement Therapy ◽  
End Stage

The retention of uremic toxins and their pathological effects occurs in the advanced phases of chronic kidney disease (CKD), mainly in stage 5, when the implementation of conventional thrice-weekly hemodialysis is the prevalent and life-saving treatment. However, the start of hemodialysis is associated with both an acceleration of the loss of residual kidney function (RKF) and the shift to an increased intake of proteins, which are precursors of uremic toxins. In this phase, hemodialysis treatment is the only way to remove toxins from the body, but it can be largely inefficient in the case of high molecular weight and/or protein-bound molecules. Instead, even very low levels of RKF are crucial for uremic toxins excretion, which in most cases are protein-derived waste products generated by the intestinal microbiota. Protection of RKF can be obtained even in patients with end-stage kidney disease (ESKD) by a gradual and soft shift to kidney replacement therapy (KRT), for example by combining a once-a-week hemodialysis program with a low or very low-protein diet on the extra-dialysis days. This approach could represent a tailored strategy aimed at limiting the retention of both inorganic and organic toxins. In this paper, we discuss the combination of upstream (i.e., reduced production) and downstream (i.e., increased removal) strategies to reduce the concentration of uremic toxins in patients with ESKD during the transition phase from pure conservative management to full hemodialysis treatment.

scholarly journals Measures of repolarization variability predict ventricular arrhythmogenesis in heptanol-treated Langendorff-perfused mouse hearts

2021 ◽  
Vol 4 ◽  
pp. 125-134
Author(s):  
Gary Tse ◽  
Guoliang Hao ◽  
Sharen Lee ◽  
Jiandong Zhou ◽  
Qingpeng Zhang ◽  
...  
Keyword(s):  
Ventricular Arrhythmogenesis

scholarly journals Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment

1999 ◽  
Vol 14 (8) ◽  
pp. 2050-2051 ◽  
Author(s):  
D. Kuypers ◽  
J. Vanwalleghem ◽  
B. Maes ◽  
T. Messiaen ◽  
Y. Vanrenterghem ◽  
...  
Keyword(s):  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Hemodialysis Treatment

MO746CARDIAC REMODELING AND PULMONARY HYPERTENSION IN HEMODIALYSIS PATIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Ekaterina Borodulina ◽  
Alexander M Shutov
Keyword(s):  
Pulmonary Hypertension ◽  
Left Ventricular Hypertrophy ◽  
Arterial Pressure ◽  
Ventricular Hypertrophy ◽  
Pulmonary Arterial Pressure ◽  
Hemodialysis Patients ◽  
Left Ventricular ◽  
Hemodialysis Treatment ◽  
Systolic Pulmonary Arterial Pressure ◽  
Pulmonary Arterial

Abstract Background and Aims An important predictor of cardiovascular mortality and morbidity in hemodialysis patients is left ventricular hypertrophy. Also, pulmonary hypertension is a risk factor for mortality and cardiovascular events in hemodialysis patients. The aim of this study was to investigate cardiac remodeling and the dynamics of pulmonary arterial pressure during a year-long hemodialysis treatment and to evaluate relationship between pulmonary arterial pressure and blood flow in arteriovenous fistula. Method Hemodialysis patients (n=88; 42 males, 46 females, mean age was 51.7±13.0 years) were studied. Echocardiography and Doppler echocardiography were performed in the beginning of hemodialysis treatment and after a year. Echocardiographic evaluation was carried out on the day after dialysis. Left ventricular mass index (LVMI) was calculated. Left ventricular ejection fraction (LVEF) was measured by the echocardiographic Simpson method. Arteriovenous fistula flow was determined by Doppler echocardiography. Pulmonary hypertension was diagnosed according to criteria of Guidelines for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology. Results Pulmonary hypertension was diagnosed in 47 (53.4%) patients. Left ventricular hypertrophy was revealed in 71 (80.7%) patients. Only 2 (2.3%) patients had LVEF<50%. At the beginning of hemodialysis correlation was detected between systolic pulmonary arterial pressure and LVMI (r=0.52; P<0.001). Systolic pulmonary arterial pressure negatively correlated with left ventricular ejection fraction (r=-0.20; P=0.04). After a year of hemodialysis treatment LVMI decreased from 140.49±42.95 to 123.25±39.27 g/m2 (р=0.006) mainly due to a decrease in left ventricular end-diastolic dimension (from 50.23±6.48 to 45.13±5.24 mm, p=0.04) and systolic pulmonary arterial pressure decreased from 44.83±14.53 to 39.14±10.29 mmHg (р=0.002). Correlation wasn’t found between systolic pulmonary arterial pressure and arteriovenous fistula flow (r=0.17; p=0.4). Conclusion Pulmonary hypertension was diagnosed in half of patients at the beginning of hemodialysis treatment. Pulmonary hypertension in hemodialysis patients was associated with left ventricular hypertrophy, systolic left ventricular dysfunction. After a year-long hemodialysis treatment, a regress in left ventricular hypertrophy and a partial decrease in pulmonary arterial pressure were observed. There wasn’t correlation between arteriovenous fistula flow and systolic pulmonary arterial pressure.

scholarly journals Overview of hemodialysis treatment funded by the Brazilian Unified Health System - An economic perspective

2015 ◽  
Vol 37 (3) ◽  
Author(s):  
Fabiana Gatti de Menezes ◽  
Daniela Veit Barreto ◽  
Rodrigo Martins Abreu ◽  
Fabiana Roveda ◽  
Roberto Flavio Silva Pecoits Filho
Keyword(s):  
Health System ◽  
Economic Perspective ◽  
Hemodialysis Treatment ◽  
Unified Health System
Sign in / Sign up

Export Citation Format

Share Document